{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:10:52Z","timestamp":1770819052767,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2011,6,20]],"date-time":"2011-06-20T00:00:00Z","timestamp":1308528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Optimal doses of von Willebrand Factor\/Factor VIII (VWF\/FVIII) concentrates for surgical procedures in patients with VWD need to be determined. A prospective, multicenter study was performed that included an initial pharmacokinetic (PK) assessment following a standard dose of VWF\/FVIII concentrate (Humate\u2010P<jats:sup>\u00ae<\/jats:sup>) to determine individual PK parameters and guide therapeutic dosing during surgery. Forty one subjects received 60\u2003IU kg<jats:sup>\u22121<\/jats:sup> VWF: RCo. Median plasma levels, half\u2010life, mean change from baseline and <jats:italic>in vivo<\/jats:italic> recovery (IVR) values were determined for VWF:RCo, VWF:Ag, and FVIII: C, and area under the plasma time\u2010concentration curve (AUC), mean residence time (MRT), clearance, volume of distribution and dose linearity were also assessed for VWF:RCo at various time points. Median baseline VWF:RCo level was 13\u2003IU dL<jats:sup>\u22121<\/jats:sup> (range, 6\u2013124); with a mean change from baseline &gt;100\u2003IU dL<jats:sup>\u22121<\/jats:sup> immediately after the infusion, decreasing to 10\u2003IU dL<jats:sup>\u22121<\/jats:sup> at 48\u2003h postinfusion. The group median incremental <jats:italic>in vivo<\/jats:italic> recovery (IVR) for VWF:RCo was 2.4\u2003IU dL<jats:sup>\u22121<\/jats:sup> per IU kg<jats:sup>\u22121<\/jats:sup>, for VWF:Ag 2.3\u2003IU dL<jats:sup>\u22121<\/jats:sup>\u2003kg<jats:sup>\u22121<\/jats:sup> and for FVIII:C was 2.7\u2003IU dL<jats:sup>\u22121<\/jats:sup> per IU kg<jats:sup>\u22121<\/jats:sup>. When analysing individual recovery values on repeated infusions, a very weak correlation was observed between presurgery IVR and IVR for both VWF:RCo and FVIII, measured at various times just prior to and after the surgical procedure. Although group median values were fairly consistent among repeated IVR measurements, the intra\u2010individual IVR values for FVIII and VWF:RCo with repeated infusions showed a large degree of variability. IVR values obtained from pharmacokinetic analyses performed in advance of anticipated surgery do not reliably predict postinfusion circulating levels of VWF:RCo or FVIII attained preoperatively or with subsequent peri\u2010operative infusions.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2011.02583.x","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T04:09:04Z","timestamp":1308629344000},"page":"752-758","source":"Crossref","is-referenced-by-count":24,"title":["Presurgical pharmacokinetic analysis of a von Willebrand factor\/factor VIII (VWF\/FVIII) concentrate in patients with von Willebrand\u2019s disease (VWD) has limited value in dosing for surgery"],"prefix":"10.1111","volume":"17","author":[{"given":"J.","family":"DI PAOLA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"LETHAGEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"GILL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"MANNUCCI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"MANCO\u2010JOHNSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"BERNSTEIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. L.","family":"NICHOLS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. E.","family":"BERGMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,6,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1642471"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00809.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200406000-00006"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.2.450"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11124"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-0037-1614448","article-title":"Safety and efficacy of continuous infusion of a combined factor VIII\u2010von Willebrand factor (vWF) concentrate (Haemate\u2010P) in patients with von Willebrand disease","volume":"81","author":"Lubetsky A","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1612977"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02588.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/63.2.210"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.02845.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI109795"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3033.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3048.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01836069"},{"key":"e_1_2_6_16_2","first-page":"173","article-title":"The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease","volume":"71","author":"Hanna WT","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3001.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1653868"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01401.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2011.02583.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2011.02583.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T06:27:17Z","timestamp":1697351237000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2011.02583.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,20]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1111\/j.1365-2516.2011.02583.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2011.02583.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,20]]}}}